<!DOCTYPE html>
<html lang="it">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Terapia Neuropsichiatrica nella Demenza</title>
    <style>
        body {
            font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
            line-height: 1.5;
            margin: 0;
            padding: 20px;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            min-height: 100vh;
        }
        
        /* Print Styles for Pocket Cards */
        @media print {
            body {
                background: white !important;
                padding: 0 !important;
                margin: 0 !important;
                font-size: 8pt !important;
                line-height: 1.2 !important;
            }
            
            .container {
                box-shadow: none !important;
                border-radius: 0 !important;
                max-width: none !important;
                width: 100% !important;
                background: white !important;
            }
            
            .header {
                background: #2c3e50 !important;
                color: white !important;
                padding: 8px !important;
                page-break-after: avoid !important;
            }
            
            h1 {
                font-size: 12pt !important;
                margin: 0 !important;
                text-shadow: none !important;
            }
            
            h2 {
                font-size: 10pt !important;
                margin: 8px 0 4px 0 !important;
                page-break-after: avoid !important;
            }
            
            h3 {
                font-size: 9pt !important;
                margin: 6px 0 3px 0 !important;
            }
            
            .content {
                padding: 8px !important;
            }
            
            .principles-grid {
                display: block !important;
                margin: 8px 0 !important;
            }
            
            .principle-card {
                margin: 4px 0 !important;
                padding: 6px !important;
                border: 1px solid #ccc !important;
                background: white !important;
                border-radius: 3px !important;
                box-shadow: none !important;
                page-break-inside: avoid !important;
            }
            
            .principle-title {
                font-size: 8pt !important;
                font-weight: bold !important;
                margin-bottom: 3px !important;
            }
            
            .pattern-table, .drug-table {
                width: 100% !important;
                border-collapse: collapse !important;
                margin: 6px 0 !important;
                font-size: 7pt !important;
                page-break-inside: avoid !important;
            }
            
            .pattern-table th, .drug-table th {
                background: #f0f0f0 !important;
                color: black !important;
                padding: 4px 2px !important;
                border: 1px solid #ccc !important;
                font-size: 7pt !important;
            }
            
            .pattern-table td, .drug-table td {
                padding: 3px 2px !important;
                border: 1px solid #ccc !important;
                font-size: 6pt !important;
                line-height: 1.1 !important;
            }
            
            .drug-section {
                margin: 8px 0 !important;
                border: 1px solid #ccc !important;
                border-radius: 0 !important;
                box-shadow: none !important;
                page-break-inside: avoid !important;
            }
            
            .drug-header {
                background: #e0e0e0 !important;
                color: black !important;
                padding: 4px !important;
                font-size: 9pt !important;
            }
            
            .black-box {
                background: #ffebee !important;
                color: black !important;
                padding: 6px !important;
                border: 2px solid #e74c3c !important;
                margin: 4px 0 !important;
            }
            
            .quick-guide {
                background: #f8f9fa !important;
                color: black !important;
                padding: 8px !important;
                border: 1px solid #ccc !important;
                margin: 8px 0 !important;
            }
            
            .symptom-card {
                background: white !important;
                border: 1px solid #ddd !important;
                padding: 4px !important;
                margin: 3px 0 !important;
            }
            
            .symptom-title {
                font-size: 8pt !important;
                font-weight: bold !important;
                margin-bottom: 2px !important;
            }
            
            .treatment-line {
                font-size: 6pt !important;
                margin: 1px 0 !important;
                padding-left: 8px !important;
            }
            
            .note {
                background: white !important;
                border: 1px solid #ccc !important;
                padding: 6px !important;
                margin: 6px 0 !important;
                font-size: 7pt !important;
            }
            
            .no-print {
                display: none !important;
            }
            
            /* Card Format - A5 size for pocket cards */
            @page {
                size: A5;
                margin: 0.5cm;
            }
        }
        
        .print-controls {
            position: fixed;
            top: 20px;
            right: 20px;
            z-index: 1000;
            background: white;
            padding: 15px;
            border-radius: 10px;
            box-shadow: 0 4px 12px rgba(0,0,0,0.2);
        }
        
        .print-btn {
            background: linear-gradient(135deg, #27ae60, #2ecc71);
            color: white;
            border: none;
            padding: 12px 20px;
            border-radius: 8px;
            cursor: pointer;
            font-weight: bold;
            margin: 5px;
            font-size: 14px;
            transition: all 0.3s ease;
        }
        
        .print-btn:hover {
            transform: translateY(-2px);
            box-shadow: 0 4px 12px rgba(39, 174, 96, 0.3);
        }
        
        .print-btn.secondary {
            background: linear-gradient(135deg, #3498db, #5dade2);
        }
        
        .print-info {
            font-size: 12px;
            color: #666;
            margin-top: 10px;
            text-align: center;
        }
        
        .container {
            max-width: 1400px;
            margin: 0 auto;
            background: white;
            border-radius: 15px;
            box-shadow: 0 20px 40px rgba(0,0,0,0.1);
            overflow: hidden;
        }
        
        .header {
            background: linear-gradient(135deg, #2c3e50, #34495e);
            color: white;
            padding: 30px;
            text-align: center;
        }
        
        h1 {
            margin: 0;
            font-size: 2.5em;
            font-weight: 700;
            text-shadow: 2px 2px 4px rgba(0,0,0,0.3);
        }
        
        .content {
            padding: 30px;
        }
        
        h2 {
            color: #2c3e50;
            border-left: 5px solid #3498db;
            padding-left: 15px;
            margin-top: 40px;
            margin-bottom: 20px;
            font-size: 1.6em;
        }
        
        h3 {
            color: #27ae60;
            margin-top: 25px;
            margin-bottom: 15px;
            font-size: 1.3em;
        }
        
        .principles-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(350px, 1fr));
            gap: 25px;
            margin: 25px 0;
        }
        
        .principle-card {
            background: linear-gradient(135deg, #f8f9fa, #e9ecef);
            border-radius: 12px;
            padding: 25px;
            border-left: 5px solid #3498db;
            box-shadow: 0 5px 15px rgba(0,0,0,0.1);
            transition: transform 0.3s ease;
        }
        
        .principle-card:hover {
            transform: translateY(-5px);
        }
        
        .principle-title {
            color: #2c3e50;
            font-weight: bold;
            font-size: 1.2em;
            margin-bottom: 10px;
        }
        
        .pattern-table {
            width: 100%;
            border-collapse: collapse;
            margin: 25px 0;
            border-radius: 12px;
            overflow: hidden;
            box-shadow: 0 8px 25px rgba(0,0,0,0.1);
        }
        
        .pattern-table th {
            background: linear-gradient(135deg, #34495e, #2c3e50);
            color: white;
            padding: 15px;
            text-align: left;
            font-weight: bold;
            font-size: 14px;
        }
        
        .pattern-table td {
            padding: 12px 15px;
            border-bottom: 1px solid #e0e0e0;
            vertical-align: top;
            font-size: 13px;
        }
        
        .dementia-type {
            font-weight: bold;
            color: #2c3e50;
            background: linear-gradient(135deg, #ecf0f1, #bdc3c7);
        }
        
        .drug-section {
            margin: 30px 0;
            border-radius: 15px;
            overflow: hidden;
            box-shadow: 0 8px 20px rgba(0,0,0,0.1);
        }
        
        .drug-header {
            padding: 20px 25px;
            color: white;
            font-size: 1.4em;
            font-weight: bold;
            text-align: center;
        }
        
        .antidepressants { background: linear-gradient(135deg, #3498db, #2980b9); }
        .antipsychotics { background: linear-gradient(135deg, #e74c3c, #c0392b); }
        .others { background: linear-gradient(135deg, #f39c12, #e67e22); }
        
        .drug-table {
            width: 100%;
            border-collapse: collapse;
        }
        
        .drug-table th {
            background: #34495e;
            color: white;
            padding: 15px 10px;
            text-align: left;
            font-weight: bold;
            font-size: 13px;
        }
        
        .drug-table td {
            padding: 12px 10px;
            border-bottom: 1px solid #e0e0e0;
            vertical-align: top;
            font-size: 12px;
        }
        
        .drug-name {
            font-weight: bold;
            color: #2c3e50;
        }
        
        .dosage {
            color: #27ae60;
            font-weight: 500;
        }
        
        .warning {
            color: #e74c3c;
            font-weight: 500;
        }
        
        .black-box {
            background: linear-gradient(135deg, #e74c3c, #c0392b);
            color: white;
            padding: 20px;
            border-radius: 10px;
            margin: 20px 0;
            border-left: 5px solid #a93226;
        }
        
        .quick-guide {
            background: linear-gradient(135deg, #16a085, #1abc9c);
            color: white;
            padding: 25px;
            border-radius: 15px;
            margin: 30px 0;
        }
        
        .quick-guide h3 {
            color: white;
            margin-top: 0;
        }
        
        .symptom-card {
            background: rgba(255,255,255,0.1);
            border-radius: 10px;
            padding: 15px;
            margin: 15px 0;
            border-left: 4px solid #f1c40f;
        }
        
        .symptom-title {
            font-weight: bold;
            font-size: 1.1em;
            margin-bottom: 8px;
        }
        
        .treatment-line {
            margin: 5px 0;
            padding-left: 15px;
        }
        
        .highlight {
            background: #fff3cd;
            padding: 2px 6px;
            border-radius: 4px;
            color: #856404;
            font-weight: 500;
        }
        
        .phase-early { background-color: #e8f5e9; }
        .phase-intermediate { background-color: #fff3e0; }
        .phase-advanced { background-color: #ffebee; }
        
        tr:nth-child(even) {
            background-color: #f8f9fa;
        }
        
        tr:hover {
            background-color: #e3f2fd;
            transition: background-color 0.3s ease;
        }
        
        .emoji {
            font-size: 1.2em;
            margin-right: 8px;
        }
        
        .note {
            background: #e8f4fd;
            border-left: 4px solid #2196f3;
            padding: 15px;
            margin: 20px 0;
            border-radius: 5px;
        }
    </style>
</head>
<body>
    <!-- Print Controls -->
    <div class="print-controls no-print">
        <button class="print-btn" onclick="window.print()">üñ®Ô∏è Stampa Schema Completo</button>
        <button class="print-btn secondary" onclick="printPocketCard()">üìã Stampa Card Tascabile</button>
        <div class="print-info">
            üí° Per card plastificate:<br>
            Formato A5 - 148√ó210mm<br>
            Stampa fronte/retro
        </div>
    </div>

    <script>
        function printPocketCard() {
            // Create a new window with optimized pocket card layout
            const printWindow = window.open('', '_blank');
            printWindow.document.write(`
                <!DOCTYPE html>
                <html>
                <head>
                    <title>Card Tascabile - Terapia Neuropsichiatrica Demenza</title>
                    <style>
                        @media print {
                            @page { size: A5; margin: 0.3cm; }
                        }
                        body { 
                            font-family: Arial, sans-serif; 
                            font-size: 7pt; 
                            line-height: 1.1; 
                            margin: 0; 
                            padding: 5px;
                        }
                        .card-header { 
                            background: #2c3e50; 
                            color: white; 
                            text-align: center; 
                            padding: 4px; 
                            font-size: 10pt; 
                            font-weight: bold;
                            margin-bottom: 5px;
                        }
                        .section { 
                            margin: 4px 0; 
                            border: 1px solid #ddd; 
                            padding: 3px;
                        }
                        .section-title { 
                            background: #f0f0f0; 
                            font-weight: bold; 
                            padding: 2px; 
                            font-size: 8pt;
                        }
                        .drug-item { 
                            margin: 2px 0; 
                            padding-left: 8px;
                        }
                        .drug-name { font-weight: bold; }
                        .dosage { color: #27ae60; }
                        .warning { color: #e74c3c; font-size: 6pt; }
                        .quick-ref { 
                            background: #e8f4fd; 
                            padding: 3px; 
                            margin: 2px 0;
                            font-size: 6pt;
                        }
                        .symptoms { 
                            display: grid; 
                            grid-template-columns: 1fr 1fr; 
                            gap: 3px;
                        }
                        .symptom { 
                            border: 1px solid #ccc; 
                            padding: 2px; 
                            font-size: 6pt;
                        }
                        .highlight { background: #fff3cd; padding: 1px 2px; }
                    </style>
                </head>
                <body>
                    <div class="card-header">üß† TERAPIA NEUROPSICHIATRICA DEMENZA</div>
                    
                    <div class="section">
                        <div class="section-title">‚ö° PRINCIPI BASE</div>
                        <div style="font-size: 6pt;">
                            ‚Ä¢ <strong>Non farmacologico PRIMA</strong> (rimuovi trigger)<br>
                            ‚Ä¢ <strong>Start Low, Go Slow</strong> (met√† dose anziano)<br>
                            ‚Ä¢ <strong>AD:</strong> ottimizza anticolinesterasici + memantina
                        </div>
                    </div>
                    
                    <div class="section">
                        <div class="section-title">üíä ANTIDEPRESSIVI</div>
                        <div class="drug-item">
                            <span class="drug-name">Escitalopram</span> <span class="dosage">5‚Üí10-20mg</span><br>
                            <span style="font-size: 6pt;">Depressione, ansia, agitazione non psicotica</span>
                        </div>
                        <div class="drug-item">
                            <span class="drug-name">Vortioxetina</span> <span class="dosage">5‚Üí10mg</span><br>
                            <span style="font-size: 6pt;">Depressione + apatia, meno effetti cognitivi</span>
                        </div>
                        <div class="drug-item">
                            <span class="drug-name">Mirtazapina</span> <span class="dosage">7.5-15mg sera</span><br>
                            <span style="font-size: 6pt;">Insonnia + depressione, aumenta appetito</span>
                        </div>
                        <div class="drug-item">
                            <span class="drug-name">Trazodone</span> <span class="dosage">25-50mg sera</span><br>
                            <span style="font-size: 6pt;">Insonnia (effetto rapido 30-60min)</span>
                        </div>
                        <div class="drug-item">
                            <span class="drug-name">Bupropione</span> <span class="dosage">75‚Üí150mg</span><br>
                            <span style="font-size: 6pt;">Apatia marcata (attivante)</span>
                        </div>
                    </div>
                    
                    <div class="section">
                        <div class="section-title">üö® ANTIPSICOTICI</div>
                        <div class="warning" style="background: #ffebee; padding: 2px; margin-bottom: 3px;">
                            ‚ö†Ô∏è BLACK BOX: +1.5-1.7x mortalit√†, eventi CV
                        </div>
                        <div class="drug-item">
                            <span class="drug-name">Quetiapina</span> <span class="dosage">25mg‚Üí50-450mg</span><br>
                            <span style="font-size: 6pt;"><strong>1¬™ SCELTA LBD/PARKINSON</strong> - Molto sedativa</span>
                        </div>
                        <div class="drug-item">
                            <span class="drug-name">Risperidone</span> <span class="dosage">0.25mg‚Üí0.5-1mg x2</span><br>
                            <span style="font-size: 6pt;">Approvato agitazione AD - Alto rischio EPS</span>
                        </div>
                        <div class="drug-item">
                            <span class="drug-name">Aripiprazolo</span> <span class="dosage">2.5-5‚Üí10-15mg</span><br>
                            <span style="font-size: 6pt;">Basso rischio CV/metabolico - Pu√≤ dare acatisia</span>
                        </div>
                        <div class="drug-item">
                            <span class="drug-name">Brexpiprazolo</span> <span class="dosage">0.25-0.5‚Üímax 4mg</span><br>
                            <span style="font-size: 6pt;">FDA approvato AD - Profilo favorevole</span>
                        </div>
                    </div>
                    
                    <div class="section">
                        <div class="section-title">‚ö° GUIDA RAPIDA PER SINTOMO</div>
                        <div class="symptoms">
                            <div class="symptom">
                                <strong>AGITAZIONE</strong><br>
                                Non psicotica: SSRI, Trazodone<br>
                                Psicotica: Quetiapina (LBD), Risperidone (AD)
                            </div>
                            <div class="symptom">
                                <strong>DEPRESSIONE</strong><br>
                                +Apatia: Vortioxetina, Bupropione<br>
                                +Ansia: SSRI<br>
                                +Insonnia: Mirtazapina
                            </div>
                            <div class="symptom">
                                <strong>INSONNIA</strong><br>
                                1¬™: Melatonina 10mg<br>
                                2¬™: Trazodone 50mg<br>
                                +Psicosi: Quetiapina 25-50mg
                            </div>
                            <div class="symptom">
                                <strong>PSICOSI</strong><br>
                                LBD: Quetiapina<br>
                                AD: Risperidone, Aripiprazolo<br>
                                Evitare in Parkinson
                            </div>
                            <div class="symptom">
                                <strong>APATIA</strong><br>
                                Evitare SSRI<br>
                                1¬™: Bupropione, Vortioxetina<br>
                                Resistente: Metilfenidato
                            </div>
                            <div class="symptom">
                                <strong>PATTERN DEMENZE</strong><br>
                                AD: depressione‚Üíagitazione‚Üíallucinazioni<br>
                                LBD: allucinazioni precoci<br>
                                FTD: disinibizione, apatia
                            </div>
                        </div>
                    </div>
                    
                    <div class="section">
                        <div class="section-title">‚ö†Ô∏è ATTENZIONI SPECIALI</div>
                        <div style="font-size: 6pt;">
                            ‚Ä¢ <strong>QTc:</strong> Citalopram, Quetiapina (ECG basale + follow-up)<br>
                            ‚Ä¢ <strong>Parkinsonismo:</strong> Evitare antipsicotici in LBD (eccetto Quetiapina)<br>
                            ‚Ä¢ <strong>Benzodiazepine:</strong> Solo breve termine, rischio paradosso<br>
                            ‚Ä¢ <strong>Sindrome metabolica:</strong> Olanzapina (peso, diabete)<br>
                            ‚Ä¢ <strong>Cadute:</strong> Tutti i psicofarmaci aumentano rischio
                        </div>
                    </div>
                    
                    <div style="text-align: center; font-size: 6pt; margin-top: 5px; color: #666;">
                        Guida rapida - Consultare sempre linee guida complete
                    </div>
                </body>
                </html>
            `);
            printWindow.document.close();
            printWindow.focus();
            setTimeout(() => {
                printWindow.print();
                printWindow.close();
            }, 250);
        }
    </script>
    <div class="container">
        <div class="header">
            <h1>üß† SCHEMI DI TERAPIA NEUROPSICHIATRICA NELLA DEMENZA</h1>
        </div>
        
        <div class="content">
            <h2><span class="emoji">üéØ</span>1. Principi Guida al Trattamento</h2>
            
            <div class="principles-grid">
                <div class="principle-card">
                    <div class="principle-title">Approccio Non Farmacologico PRIMA di tutto</div>
                    <ul>
                        <li><strong>Identificare e rimuovere</strong> i fattori scatenanti (dolore, infezioni, ambiente stressante)</li>
                        <li><strong>Educare</strong> il paziente e il caregiver su strategie comportamentali</li>
                        <li><strong>Trattare solo</strong> i sintomi che causano stress significativo al paziente o mettono a rischio la sicurezza</li>
                    </ul>
                </div>
                
                <div class="principle-card">
                    <div class="principle-title">Regola "Start Low, Go Slow"</div>
                    <ul>
                        <li><strong>Iniziare</strong> con il dosaggio pi√π basso possibile (o met√† dose rispetto a un adulto giovane)</li>
                        <li><strong>Titolare lentamente</strong> la dose, monitorando attentamente la risposta e gli effetti collaterali</li>
                    </ul>
                </div>
                
                <div class="principle-card">
                    <div class="principle-title">Verifica Preliminare in Alzheimer (AD)</div>
                    <ul>
                        <li>Prima di introdurre psicofarmaci, assicurarsi che il paziente sia in <strong>terapia ottimale</strong> con anticolinesterasici (Donepezil, Rivastigmina, Galantamina) e/o Memantina</li>
                        <li>Questi farmaci possono <strong>migliorare alcuni sintomi comportamentali</strong></li>
                    </ul>
                </div>
            </div>

            <h2><span class="emoji">üìä</span>2. Pattern Caratteristici dei Sintomi Neuropsichiatrici (NPS)</h2>
            
            <table class="pattern-table">
                <thead>
                    <tr>
                        <th style="width: 15%;">Tipo Demenza</th>
                        <th style="width: 28%;">Fase Precoce</th>
                        <th style="width: 28%;">Fase Intermedia</th>
                        <th style="width: 29%;">Fase Avanzata</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td class="dementia-type">AD</td>
                        <td class="phase-early">Depressione, ansia, apatia, irritabilit√†</td>
                        <td class="phase-intermediate">Agitazione, disturbi del sonno, deliri</td>
                        <td class="phase-advanced">Allucinazioni, disinibizione, comportamenti motori aberranti</td>
                    </tr>
                    <tr>
                        <td class="dementia-type">VD</td>
                        <td class="phase-early">Irritabilit√†, depressione, disturbi sonno</td>
                        <td class="phase-intermediate">Ansia, apatia</td>
                        <td class="phase-advanced">-</td>
                    </tr>
                    <tr>
                        <td class="dementia-type">LBD</td>
                        <td class="phase-early">Allucinazioni visive, apatia, depressione, ansia, disturbi del sonno (RBD)</td>
                        <td class="phase-intermediate">Deliri, cambi appetito, irritabilit√†, agitazione, comp. motori aberranti</td>
                        <td class="phase-advanced">-</td>
                    </tr>
                    <tr>
                        <td class="dementia-type">bvFTD</td>
                        <td class="phase-early">Perdita empatia, apatia, disinibizione, iperfagia (dolci), comp. motori</td>
                        <td class="phase-intermediate">Agitazione, depressione, ansia</td>
                        <td class="phase-advanced">-</td>
                    </tr>
                    <tr>
                        <td class="dementia-type">PPA (afasie)</td>
                        <td class="phase-early">Prevalentemente ansia, depressione, apatia (la semantica anche disinibizione)</td>
                        <td class="phase-intermediate">Tendenza a sviluppare sintomi simili a bvFTD</td>
                        <td class="phase-advanced">-</td>
                    </tr>
                    <tr>
                        <td class="dementia-type">PCA</td>
                        <td class="phase-early">Limitati / Ansia, depressione, apatia</td>
                        <td class="phase-intermediate">-</td>
                        <td class="phase-advanced">-</td>
                    </tr>
                </tbody>
            </table>

            <h2><span class="emoji">üíä</span>3. Guida alla Terapia Farmacologica per Classe</h2>

            <div class="drug-section">
                <div class="drug-header antidepressants">A) ANTIDEPRESSIVI</div>
                <table class="drug-table">
                    <thead>
                        <tr>
                            <th style="width: 25%;">Farmaco (Classe)</th>
                            <th style="width: 35%;">Indicazioni Principali / Note</th>
                            <th style="width: 25%;">Posologia Iniziale / Note sulla Dose</th>
                            <th style="width: 15%;">‚ö†Ô∏è Effetti Collaterali / Avvertenze</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td class="drug-name">Escitalopram / Citalopram<br><em>(SSRI)</em></td>
                            <td>Depressione, ansia, agitazione (non psicotica)</td>
                            <td class="dosage">Escitalopram: 5 mg/die ‚Üí 10-20 mg/die<br>Citalopram: 10 mg/die ‚Üí 20-30 mg/die</td>
                            <td class="warning">Peggiorano apatia. Rischio QTc. Nausea, insonnia</td>
                        </tr>
                        <tr>
                            <td class="drug-name">Sertralina<br><em>(SSRI)</em></td>
                            <td>Simile a Escitalopram. Utile in agitazione non psicotica</td>
                            <td class="dosage">25 mg/die ‚Üí 50-150 mg/die</td>
                            <td class="warning">Profilo di sicurezza generalmente buono</td>
                        </tr>
                        <tr>
                            <td class="drug-name">Vortioxetina<br><em>(Multimodale)</em></td>
                            <td>Depressione con apatia e deficit cognitivi. Azione prominente sull'ansia</td>
                            <td class="dosage">5 mg/die ‚Üí 10 mg/die (fino a 20 mg/die)</td>
                            <td class="warning">Meno apatia rispetto a SSRI. Nausea principale effetto collaterale</td>
                        </tr>
                        <tr>
                            <td class="drug-name">Mirtazapina<br><em>(NaSSA)</em></td>
                            <td>Insonnia + Depressione/Ansia. Aumenta l'appetito</td>
                            <td class="dosage">Insonnia: 7.5-15 mg sera<br>Depressione: 30-45 mg sera</td>
                            <td class="warning">Sedazione (sfruttata a basse dosi). Pochi effetti su QTc</td>
                        </tr>
                        <tr>
                            <td class="drug-name">Bupropione<br><em>(NDRI)</em></td>
                            <td>Depressione con apatia marcata (antidepressivo "attivante")</td>
                            <td class="dosage">75 mg/die ‚Üí 150 mg/die (rilascio prolungato)</td>
                            <td class="warning">Controindicato in epilessia. Non causa sedazione</td>
                        </tr>
                        <tr>
                            <td class="drug-name">Trazodone<br><em>(SARI)</em></td>
                            <td>Insonnia. Ad alte dosi per depressione/agitazione. Effetto rapido (30-60 min)</td>
                            <td class="dosage">Insonnia: 25-50 mg sera ‚Üí 100 mg max<br>Umore: fino a 150-300 mg/die</td>
                            <td class="warning">Ipotensione ortostatica, sedazione, priapismo (raro)</td>
                        </tr>
                    </tbody>
                </table>
            </div>

            <div class="drug-section">
                <div class="drug-header antipsychotics">B) ANTIPSICOTICI (Preferire Atipici)</div>
                
                <div class="black-box">
                    <strong>‚ö†Ô∏è BLACK BOX WARNING:</strong> Aumento di 1.5-1.7 volte del rischio di mortalit√† per tutte le cause, eventi cerebrovascolari e aritmie. Usare per il minor tempo possibile alla minima dose efficace.
                </div>
                
                <table class="drug-table">
                    <thead>
                        <tr>
                            <th style="width: 25%;">Farmaco (Classe)</th>
                            <th style="width: 35%;">Indicazioni Principali / Note</th>
                            <th style="width: 25%;">Posologia Iniziale / Titolazione</th>
                            <th style="width: 15%;">‚ö†Ô∏è Effetti Collaterali / Avvertenze</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td class="drug-name">Quetiapina<br><em>(Atipico)</em></td>
                            <td><span class="highlight">PRIMA LINEA</span> in Parkinson/LBD (psicosi, agitazione, insonnia). Molto sedativa</td>
                            <td class="dosage">25 mg x 1-2/die<br>Titolare ogni 2-4 gg. Dose efficace: 50-450 mg/die</td>
                            <td class="warning">Rischio parkinsonismo quasi nullo. Valutare QTc</td>
                        </tr>
                        <tr>
                            <td class="drug-name">Risperidone<br><em>(Atipico)</em></td>
                            <td>Approvato per agitazione severa in AD. Poco sedativo</td>
                            <td class="dosage">0.25 mg x 1-2/die<br>Titolare a 0.5-1 mg x 2/die</td>
                            <td class="warning">Alto rischio sintomi extrapiramidali. Aumento prolattina</td>
                        </tr>
                        <tr>
                            <td class="drug-name">Olanzapina<br><em>(Atipico)</em></td>
                            <td>Molto efficace su angoscia e agitazione marcata. Molto sedativa</td>
                            <td class="dosage">2.5 mg x 1-2/die<br>Efficaci 5-10 mg/die</td>
                            <td class="warning">Alto rischio sindrome metabolica. Rischio parkinsonismo</td>
                        </tr>
                        <tr>
                            <td class="drug-name">Aripiprazolo<br><em>(Agonista parziale D2)</em></td>
                            <td>Agitazione, psicosi. Profilo "attivante" a basse dosi</td>
                            <td class="dosage">2.5-5 mg/die<br>Titolare a 10-15 mg/die</td>
                            <td class="warning">Basso rischio CV e metabolico. Pu√≤ causare acatisia</td>
                        </tr>
                        <tr>
                            <td class="drug-name">Brexpiprazolo<br><em>(Agonista parziale D2)</em></td>
                            <td>Approvato FDA per agitazione in AD. Simile ad aripiprazolo, pi√π sedativo</td>
                            <td class="dosage">0.25-0.50 mg/die<br>Mantenere 1 sett. poi titolare. Max 4 mg</td>
                            <td class="warning">Basso rischio CV. Profilo favorevole. Effetto procognitivo</td>
                        </tr>
                        <tr>
                            <td class="drug-name">Pimavanserina<br><em>(Antagonista 5-HT2A)</em></td>
                            <td>Approvato per psicosi nella Malattia di Parkinson. Non peggiora parkinsonismo</td>
                            <td class="dosage">Specifico per M. di Parkinson</td>
                            <td class="warning">Non agisce su recettori dopaminergici</td>
                        </tr>
                    </tbody>
                </table>
            </div>

            <div class="drug-section">
                <div class="drug-header others">C) STABILIZZATORI UMORE E ALTRI FARMACI</div>
                <table class="drug-table">
                    <thead>
                        <tr>
                            <th style="width: 30%;">Farmaco (Classe)</th>
                            <th style="width: 40%;">Indicazioni Principali / Note</th>
                            <th style="width: 20%;">Posologia</th>
                            <th style="width: 10%;">‚ö†Ô∏è Avvertenze</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td class="drug-name">Gabapentin<br><em>(Antiepilettico)</em></td>
                            <td>Agitazione, ansia generalizzata</td>
                            <td class="dosage">100-300 mg x 1-3/die</td>
                            <td class="warning">Effetto sedativo marcato</td>
                        </tr>
                        <tr>
                            <td class="drug-name">Benzodiazepine<br><em>(Lorazepam, Clonazepam)</em></td>
                            <td><span class="highlight">SOLO BREVE TERMINE</span>: ansia acuta, insonnia grave, agitazione catastrofica</td>
                            <td class="dosage">Lorazepam 0.5-1 mg al bisogno</td>
                            <td class="warning">Rischio effetto paradosso, cadute, dipendenza</td>
                        </tr>
                        <tr>
                            <td class="drug-name">Metilfenidato<br><em>(Psicostimolante)</em></td>
                            <td>Apatia pura, non responsiva ad altri farmaci</td>
                            <td class="dosage">Valutare con specialista. 5 mg/mattina</td>
                            <td class="warning">Pu√≤ peggiorare ansia e psicosi</td>
                        </tr>
                        <tr>
                            <td class="drug-name">Destrometorfano + Chinidina</td>
                            <td>Sintomi pseudobulbari (riso/pianto spastico)</td>
                            <td class="dosage">Formulazione specifica (Nuedexta)</td>
                            <td class="warning">Chinidina pu√≤ causare allungamento QTc</td>
                        </tr>
                    </tbody>
                </table>
            </div>

            <div class="quick-guide">
                <h2><span class="emoji">üí°</span>4. Approccio Pratico per Sintomo (Scelta Rapida)</h2>
                
                <div class="symptom-card">
                    <div class="symptom-title">üî• AGITAZIONE</div>
                    <div class="treatment-line"><strong>Non psicotica:</strong> 1¬∞ linea ‚Üí SSRI (Citalopram, Sertralina), Trazodone</div>
                    <div class="treatment-line"><strong>Psicotica / Severa:</strong> 1¬∞ linea ‚Üí Antipsicotici atipici (in LBD Quetiapina; in AD Risperidone o Aripiprazolo/Brexpiprazolo). 2¬∞ linea ‚Üí Olanzapina (se angoscia marcata)</div>
                </div>
                
                <div class="symptom-card">
                    <div class="symptom-title">üòî DEPRESSIONE / ANSIA</div>
                    <div class="treatment-line"><strong>Con apatia:</strong> 1¬∞ linea ‚Üí Vortioxetina, Bupropione</div>
                    <div class="treatment-line"><strong>Con ansia/agitazione:</strong> 1¬∞ linea ‚Üí SSRI (Escitalopram, Sertralina)</div>
                    <div class="treatment-line"><strong>Con insonnia:</strong> 1¬∞ linea ‚Üí Mirtazapina, Trazodone</div>
                </div>
                
                <div class="symptom-card">
                    <div class="symptom-title">üò¥ INSONNIA</div>
                    <div class="treatment-line"><strong>Prima linea:</strong> Igiene del sonno + Melatonina (fino a 10 mg)</div>
                    <div class="treatment-line"><strong>1¬∞ linea farmacologica:</strong> Trazodone (50 mg) o Mirtazapina (7.5-15 mg)</div>
                    <div class="treatment-line"><strong>Se psicosi/agitazione notturna:</strong> Quetiapina (25-50 mg)</div>
                    <div class="treatment-line"><strong>Benzodiazepine:</strong> da evitare, se necessario solo per pochi giorni</div>
                </div>
                
                <div class="symptom-card">
                    <div class="symptom-title">üëª PSICOSI (DELIRI E ALLUCINAZIONI)</div>
                    <div class="treatment-line"><strong>In LBD/Parkinson-Demenza:</strong> Quetiapina prima scelta. Pimavanserina se disponibile</div>
                    <div class="treatment-line"><strong>In Alzheimer:</strong> Risperidone, Aripiprazolo, Olanzapina (bilanciare efficacia ed effetti collaterali)</div>
                </div>
                
                <div class="symptom-card">
                    <div class="symptom-title">üòê APATIA</div>
                    <div class="treatment-line"><strong>Evitare:</strong> SSRI standard</div>
                    <div class="treatment-line"><strong>1¬∞ linea:</strong> Antidepressivi attivanti (Bupropione, Vortioxetina)</div>
                    <div class="treatment-line"><strong>Casi resistenti:</strong> Valutare psicostimolanti (Metilfenidato)</div>
                </div>
                
                <div class="symptom-card">
                    <div class="symptom-title">üö´ DISINIBIZIONE / COMPORTAMENTI COMPULSIVI (tipici FTD)</div>
                    <div class="treatment-line"><strong>Gestione difficile:</strong> SSRI a volte possono aiutare sui comportamenti ripetitivi</div>
                </div>
            </div>
            
            <div class="note">
                <strong>üìã Nota Importante:</strong> Questo schema √® una guida generale. Ogni paziente richiede una valutazione individualizzata considerando comorbidit√†, interazioni farmacologiche, tollerabilit√† e risposta terapeutica. Consultare sempre le linee guida pi√π aggiornate e considerare il coinvolgimento di specialisti quando appropriato.
            </div>
        </div>
    </div>
</body>
</html>